1. Home
  2. CMDB vs ACRS Comparison

CMDB vs ACRS Comparison

Compare CMDB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CMDB

Costamare Bulkers Holdings Limited

N/A

Current Price

$15.94

Market Cap

342.8M

Sector

N/A

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.82

Market Cap

314.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMDB
ACRS
Founded
2023
2012
Country
Monaco
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
342.8M
314.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
CMDB
ACRS
Price
$15.94
$3.82
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.75
AVG Volume (30 Days)
39.7K
3.0M
Earning Date
02-12-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$799,159,000.00
$15,742,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
152.53
N/A
52 Week Low
$8.46
$1.05
52 Week High
$17.57
$4.89

Technical Indicators

Market Signals
Indicator
CMDB
ACRS
Relative Strength Index (RSI) 61.21 60.15
Support Level $14.91 $3.71
Resistance Level $15.45 $4.84
Average True Range (ATR) 0.43 0.41
MACD 0.06 0.12
Stochastic Oscillator 85.97 54.60

Price Performance

Historical Comparison
CMDB
ACRS

About CMDB Costamare Bulkers Holdings Limited

Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: